Small and Steatotic Hepatocellular Carcinoma

Percutaneous thermoablation in an effective local curative treatment in patients with cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A).

Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules.

We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC).

No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm).

This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HCC

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34295, France

About this study

We performed 412 percutaneous thermoablations on 238 patients for HCC between January 2015 and November 2019.

All thermoablation procedures were performed percutaneously under ultrasound or CT guidance, with ou without artificial pneumothorax or ascites, with ou without lipiodol marked.

Purposes:

Tumor response upon mRECIST criteria
Progression-free survival
Overall survival
Local tumor progression
Distent liver progression
Prognostic factors

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HCC according to histological examination or Barcelona criteria
BCLC0 or A
Measurable targets according to mRECIST v1.1
Child A or B7 cirrhosis
HCC < 4 cm, < 3 nodules, Age ≥ 18 years
No extrahepatic metastasis, no vascular invasion
Performance status 0 or 1
Thrombocytes ≥ 50 000/mm3, TP > 50%

Exclusion criteria

Follow-up < 1month
Lobar/main portal venous thrombus
Abundant ascites
Antecedent of bilio-digestive anastomosis or endoscopic sphincterotomy
Combined treatment with embolization or chemo-embolization

Treatment and study plan

Primary outcomes

Thermal ablations

Time frame: 1 day

Evaluation of thermal ablations (radiofrequency and microwave ablation)

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Small and Steatotic Hepatocellular Carcinoma : a Distinctive Radiological Variant With Improved Outcome After Percutenous Ablation

Important dates

Study start: 2015
Primary completion: 2019
Study completion: 2019
First posted: Feb 9, 2018
Registry last updated: May 6, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed